FluoGuide presentation at Sedermeradagen in Stockholm and Investordagen in Aalborg
FluoGuide A/S’s ("FluoGuide") presented the company and its preparation of FG001 for the proof-of-concept study progresses accordingly to plan.
At Sedermeradagen in Stockholm, Morten Albrechtsen, CEO and Andreas Kjaer, CSO presented in front of approx. 300 investors. The presentation was done in English and a filmed version is available via this link (https://www.youtube.com/watch?v=xB0Ym_fZIXE). It is also available on FluoGuide’s home page together with the presentation.
FluoGuide also presented at Investordagen in Aalborg on the 19th of November 2019. A link to the filmed version will be published on FluoGuide’s home page when available.
For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
__________________________________________________________________________________
About FluoGuide
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.
About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.